Holen Sie sich die Stockscreener-App
66.21
1.55%
1.01
Handel nachbörslich:
66.23
0.02
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.20
Offen:
$63.85
24-Stunden-Volumen:
5.72M
Relative Volume:
1.23
Marktkapitalisierung:
$25.96B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
46.35
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
+0.27%
1M Leistung:
-13.13%
6M Leistung:
-1.75%
1J Leistung:
-4.29%
1-Tages-Spanne:
$63.20
$67.29
1-Wochen-Bereich:
$63.20
$69.00
52-Wochen-Spanne:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
66.21 | 25.57B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
133.27 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
370.00 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.54 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.36 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Mizuho Adjusts Price Target on DexCom to $90 From $100, Maintains Outperform Rating - MarketScreener
Key metrics from DexCom Inc.’s quarterly dataEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Can DexCom Inc. stock deliver sustainable ROEJuly 2025 Short Interest & Weekly High Conviction Trade Ideas - newser.com
Will DexCom Inc. stock maintain momentum in 2025July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Q2 Earnings Roundup: DexCom (NASDAQ:DXCM) And The Rest Of The Patient Monitoring Segment - FinancialContent
Is DexCom Inc. a candidate for recovery playTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Is DexCom Inc. stock reversal real or fakeInsider Buying & Comprehensive Market Scan Insights - newser.com
What catalysts could drive DexCom Inc. stock higher2025 Major Catalysts & High Yield Equity Trading Tips - newser.com
DexCom Earnings Preview: What to Expect - MSN
Is DexCom Inc. stock ready for a breakoutWatch List & Verified Momentum Stock Alerts - newser.com
DexCom Inc. stock chart pattern explainedJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com
What MACD and RSI say about DexCom Inc.July 2025 Spike Watch & Reliable Price Action Trade Plans - newser.com
What does recent volatility data suggest for DexCom Inc.Options Play & Low Volatility Stock Recommendations - newser.com
Vontobel Holding Ltd. Has $1.15 Million Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM) Stock Analysis: A 53% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews
DSM Capital Partners LLC Has $125.29 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
Callan Family Office LLC Buys 16,443 Shares of DexCom, Inc. $DXCM - MarketBeat
Combining price and volume data for DexCom Inc.Analyst Upgrade & Advanced Swing Trade Entry Plans - newser.com
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know - TradingView
DexCom Earnings Preview: What To Expect - Barchart.com
Will DexCom Inc. benefit from macro trendsSell Signal & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain double digit ROEWeekly Stock Summary & Daily Volume Surge Signals - newser.com
Real time scanner hits for DexCom Inc. explained2025 Volume Leaders & Daily Risk Controlled Trade Plans - newser.com
What MACD trends signal for DexCom Inc. (DC4) stockEarnings Summary Report & Community Driven Trade Alerts - newser.com
Blair William & Co. IL Lowers Position in DexCom, Inc. $DXCM - MarketBeat
Why DexCom Inc. stock remains on watchlistsPortfolio Risk Report & Entry Point Confirmation Alerts - newser.com
DexCom Inc. stock trend forecastJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
DexCom (NASDAQ:DXCM) Receives Hold (C-) Rating from Weiss Ratings - MarketBeat
Is it too late to sell DexCom Inc.2025 Investor Takeaways & Target Return Focused Picks - newser.com
Is DexCom Inc. (DC4) stock resilient in recession scenarios2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc.DXCM - PR Newswire
DexCom Inc Stock Analysis and ForecastIPO Market Watch & Exceptional Capital Trading - earlytimes.in
Shell Asset Management Co. Buys 5,138 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Stake Raised by DAVENPORT & Co LLC - MarketBeat
Janney Montgomery Scott LLC Trims Stake in DexCom, Inc. $DXCM - MarketBeat
William Blair Maintains Bullish Stance on DexCom (DXCM) Stock - Yahoo
Citigroup Issues Pessimistic Forecast for DexCom (NASDAQ:DXCM) Stock Price - MarketBeat
DexCom (DXCM): Citigroup Lowers Price Target, Maintains "Buy" Ra - GuruFocus
What analysts say about DexCom Inc DC4 stockSector Performance Drivers & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dexcom Inc-Aktie (DXCM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stern Sadie | EVP, Chief HR Officer |
Sep 04 '25 |
Sale |
80.00 |
1,466 |
117,280 |
105,223 |
1.27%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):